
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 3, 2023

SAB BIOTHERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-39871
(Commission File Number)

85-3899721
(IRS Employer
Identification No.)

2100 East 54th Street North
Sioux Falls, South Dakota
(Address of Principal Executive Offices)

57104
(Zip Code)

Registrant's Telephone Number, Including Area Code: 605 679-6980

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, \$0.0001 par value per share	SABS	The NASDAQ Stock Market LLC
Warrants, each exercisable for one share of Common Stock at an exercise price of \$11.50 per share	SABSW	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers.

On April 3, 2023, the Nominating and Governance Committee (the “Committee”) of the Board of Directors (the “Board”) of SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) recommended the appointment of, and the Board subsequently appointed, Mr. Erick Lucera to serve as a director of the Company, effective as of April 3, 2023 until the Company’s next annual meeting of stockholders or until Mr. Lucera’s successor is duly elected and qualified. There is no arrangement or understanding between Mr. Lucera and any other person pursuant to which Mr. Lucera was selected as a director of the Company and there is no family relationship between Mr. Lucera and any of the Company’s directors or executive officers. The Company is not aware of any transaction involving Mr. Lucera which would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Mr. Lucera will receive compensation similar to the other non-employee members of the Board as described in the Company’s Proxy Statement for the 2022 Annual Meeting of Stockholders as filed with the Securities and Exchange Commission on May 25, 2022.

Erick Lucera, CFA, has served as a chief financial officer for AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company, from January 2020 until February 2023. Mr. Lucera advised AVEO’s management through a transition following AVEO’s acquisition by LG Chem, Ltd. Prior to Mr. Lucera’s time at AVEO, Mr. Lucera held chief financial officer and other senior roles at several biotechnology and medical device companies. He was previously a chief financial officer of Valeritas, a publicly traded commercial-stage medical technology company focused on developing solutions for people with diabetes, where he led Valeritas through multiple successful public offerings. Prior to Valeritas, Mr. Lucera served as chief financial officer, treasurer, and secretary of Viventia Bio (acquired by Eleven Biotherapeutics, Inc., now Sesen Bio), a biotechnology company focused on developing targeted protein therapeutics for the treatment of cancer. He also previously served as vice president, corporate development at Aratana Therapeutics, a veterinary biopharmaceutical company, where he helped grow Aratana Therapeutics product pipeline through a series of acquisitions and in-licensing transactions financed through five public and private offerings of nearly \$250 million. Mr. Lucera holds a Certification in Public Health (CPH) from Harvard University, as well as the MS from Boston College and an MBA from Indiana University Bloomington. He earned his BS in accounting from the University of Delaware.

Item 7.01. Regulation FD Disclosure.

On April 4, 2023, the Company issued a press release, a copy of which is filed herewith as Exhibit 99.1, announcing the appointment of Mr. Lucera. The information set forth in this Item 7.01 and in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and in Exhibit 99.1 shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number	Description
99.1	Press Release of the Company, dated April 4, 2023
104	Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SAB Biotherapeutics, Inc.

Date: April 4, 2023

By: /s/ Eddie J. Sullivan

Eddie J. Sullivan
Chief Executive Officer



SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors

SIOUX FALLS, S.D., April 4, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, today announced the appointment of Erick Lucera, CFA, a veteran of the biotechnology and medical device industry, with over thirty years of financial, operational and investment experience, to SAB's Board of Directors, effective April 4, 2023.

Most recently, Mr. Lucera served as chief financial officer for AVEO Oncology, a commercial stage oncology-focused biopharmaceutical company, from January 2020 until February 2023. Subsequent to the close of AVEO's acquisition by LG Chem, Ltd., he advised AVEO's management team through the transition.

"I am both excited and pleased to welcome Erick to SAB's Board of Directors," said Samuel J. Reich, Executive Chairman of SAB. "As SAB continues to advance its programs to and through important milestones, I believe that Erick's successful track record, and wealth of experience in corporate finance, will prove to be of great value to SAB. We are all looking forward to working with him."

Prior to his time at AVEO Oncology, Mr. Lucera held chief financial officer and other senior roles at several biotechnology and medical device companies. He was previously chief financial officer of Valeritas, a publicly traded commercial-stage medical technology company focused on developing solutions for people with diabetes, where he led the company through multiple successful public offerings. Prior to Valeritas, Mr. Lucera served as chief financial officer, treasurer, and secretary of Viventia Bio (acquired by Eleven Biotherapeutics, Inc., now Sesen Bio), a biotechnology company focused on developing targeted protein therapeutics for the treatment of cancer. He also previously served as vice president, corporate development at Aratana Therapeutics, a veterinary biopharmaceutical company, where he helped grow the company's product pipeline through a series of acquisitions and in-licensing transactions financed through five public and private offerings of nearly \$250 million.

"Throughout my career, I've gravitated toward innovative life science companies that are working to address therapeutic areas with high unmet medical needs," said Erick Lucera, CFA. "With its novel drug development platform and focus on immune and autoimmune disorders, SAB's value proposition is unique and exciting. I am honored to join the Board of Directors of a cutting-edge company focused on critical disease states, such as C. difficile and type 1 diabetes."

Early in his career, Mr. Lucera spent more than 15 years covering healthcare and the life sciences in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathalon Life Sciences Fund at Intrepid Capital and as head of the healthcare research team at Independence Investments. He began his career as a staff auditor and accountant at Price Waterhouse & Co. (now PwC).

Mr. Lucera holds a Certification in Public Health (CPH) from Harvard University, as well as an MS from Boston College and an MBA from Indiana University Bloomington. He earned his BS in accounting from the University of Delaware. Additionally, Mr. Lucera currently holds a CFA designation. He previously held CMA and CPA designations, now expired.

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (SAB) We are a clinical-stage biopharmaceutical company focused on the development of powerful and proprietary immunotherapeutic polyclonal human antibodies to treat and prevent infectious diseases and immune and autoimmune disorders. Our development programs include infectious diseases resulting from outbreaks and pandemics, as well as immunological, gastroenterological, and respiratory diseases that have significant mortality and health impacts on immune compromised patients. SAB has applied advanced genetic engineering and antibody science to develop Transchromosomal (Tc) Bovine™. Our versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, fully-human polyclonal immunotherapies without the need for human donors. SAB currently has multiple drug development programs underway and collaborations with the US government and global pharmaceutical companies. For more information on SAB, visit: <https://www.SAB.bio/> and follow SAB on Twitter and LinkedIn.

Forward-Looking Statements

Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including the positive impact of new members of our Board of Directors, the development and efficacy of our influenza program, C. diff. program, type 1 diabetes program, and other discovery programs, the likelihood that a patent will issue from any patent application, the results, including timing, of the development of SAB-176, SAB-185, SAB-142 and SAB-195 (including any IND filing or proposed clinical trials), financial projections and future financial and operating results (including estimated cost savings and cash runway), the outcome of and potential future government and other third-party collaborations or funded programs (including negotiations with the DoD).

These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry's results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned "Risk Factors" in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at <https://www.sec.gov/>. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

